STAT+: The FDA, urged to avoid controversy, creates a new headache with attack against UniQure
\n \t
\n
<\/BR>
\n
\n \t
\n
<\/BR><\/p>\n
There was a telling exchange during a Thursday media call set up by the Food and Drug Administration to enable a \u201csenior FDA official\u201d \u2014 he could only be quoted anonymously \u2014 to attack UniQure<\/a> and its experimental treatment for Huntington\u2019s disease.\u00a0<\/p>\n Robert Langreth, a reporter for Bloomberg, asked the senior official how long he planned to stay at the FDA.\u00a0<\/p>\n The FDA official responded, \u201cYou all know that as background, I\u2019m a professor and I\u2019m a practicing [hematology-oncology] doctor. I do miss my clinic and I miss teaching, and I miss being able to run my podcast and speak freely. But I would say that I serve at the pleasure of the [FDA] commissioner and the [health] secretary and the president, and as long as we\u2019re all in alignment \u2014 that me serving is in the best interest of the American people \u2014 I will continue to serve happily.\u201d<\/p>\n Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n